Back Hepatitis B

Hepatitis B

Coverage of the 2013 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Washington, DC, November 1-5, 2013.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

10/30/13

alt

IDWeek 2013: Entecavir and Tenofovir Both Work Well Against Hepatitis B in Clinical Practice

Entecavir (Baraclude) and tenofovir (Viread) both demonstrated potent activity against hepatitis B virus (HBV) in a Turkish study presented at the second IDWeek conference held recently in San Francisco. Entecavir appeared to have an edge with regard to hepatitis B "e" antigen (HBeAg) seroconversion, but this rose with time among people taking either drug.

alt

Read more:

FDA Warns of Hepatitis B Reactivation Risk with Immune-suppressing Cancer Drugs

The U.S. Food and Drug Administration (FDA) announced this week that it has approved labeling changes for 2 monoclonal antibody cancer drugs, ofatumumab (Arzerra) and rituximab (Rituxan), adding a stronger "black box" warning that they may cause hepatitis B virus (HBV) reactivation.

alt

Read more:

IDWeek 2013: Tenofovir May Help Prevent Mother-to-child Hepatitis B Transmission

Taking tenofovir (Viread) during the final months of pregnancy may provide extra protection against perinatal transmission of hepatitis B virus (HBV), along with immunization of the infant, according to a late-breaker presentation the Second IDWeek conference last week in San Francisco.alt

Read more:

High Rate of New Hepatitis B Among African-Americans, Study Finds

Black Americans have a higher incidence of hepatitis B virus (HBV) infection than any other racial/ethnic group, including Asian-Americans, according to a review article in the July 1, 2013, advance edition of Clinical Gastroenterology and Hepatology.

alt

Read more:

ILCA 2013: High HBV Viral Load Raises Risk of Progression to Liver Cancer

Hepatitis B patients with high HBV DNA levels, indicating active viral replication, are more likely to experience progression of abnormal liver nodules to hepatocellular carcinoma, researchers reported at the 7th International Liver Cancer Association Annual Conference (ILCA 2013) last month in Washington, DC.

alt

Read more:

Human Stem Cells Used to Create Functional Liver Cells in Mice

Researchers have discovered a way to generate functional hepatocytes (liver cells) from human stem cells, which worked as expected and increased survival when transplanted into mice with acute liver injury, researchers reported in the July 9, 2013, advance online edition of Stem Cells and Development.

alt

 

Read more:

ICAAC 2013: Liver Cancer Often Diagnosed Late with Poor Survival in People with HIV

Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage in HIV positive people with hepatitis B or C coinfection, contributing to a high mortality rate that has changed little in recent years, according to a report at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.

alt

Read more:

Hepatitis B Treatment with Entecavir Lowers Risk of Liver Cancer

Long-term treatment with entecavir (Baraclude) significantly reduces the chances of developing hepatocellular carcinoma compared with no treatment, and appears to lower the risk more than an older drug, especially for the most at-risk patients, according to a report in the July 2013 issue of Hepatology.

alt

Read more: